Clinically important change in life skills (long term) ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (long term) ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: 2. Extrapyramidal ‐ akathisia · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes adverse effects: Extrapyramidal effects ‐ akathisia ‐ short term (up… compared with OLANZAPINE (very low certainty).
1 finding from 1 review
Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early: inefficacy ‐ short term (up to 12 weeks) compared with OLANZAPINE (very low certainty).
1 finding from 1 review
Cost‐effectiveness (long term) ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: No clinically important response (as defined by the original studies) · patients with schizophrenia
It is very uncertain whether COMPARISON 5. ARIPIPRAZOLE changes global state: No clinically significant response compared with OLANZAPINE (very low certainty).
1 finding from 1 review
Mental state: as · patients with schizophrenia
1 finding from 1 review
Leaving the study early · patients with schizophrenia
COMPARISON 5. ARIPIPRAZOLE may leads to higher leaving the study early compared with OLANZAPINE (low certainty).
1 finding from 1 review
Quality of life: as · patients with schizophrenia
1 finding from 1 review
Weight gain · patients with schizophrenia
It is very uncertain whether COMPARISON 5. ARIPIPRAZOLE changes adverse effects: weight gain compared with OLANZAPINE (very low certainty).
1 finding from 1 review
General functioning ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Service use ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · schizophrenia
1 finding from 1 review
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · schizophrenia
1 finding from 1 review
Mental state: 3. Negative symptoms ‐ average endpoint score PANSS negative subscore · schizophrenia
1 finding from 1 review
Quality of life (medium term: 12 months) · schizophrenia
1 finding from 1 review
Adverse effects: 1. Sedation · schizophrenia
QUETIAPINE showed no clear difference in adverse effects: 1. Sedation compared with OLANZAPINE (moderate certainty).
1 finding from 1 review
Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication · schizophrenia
1 finding from 1 review
Adverse effects: 3. Metabolic ‐ weight significant gain · schizophrenia
QUETIAPINE probably leads to lower adverse effects: 3. Metabolic ‐ weight significant gain compared with OLANZAPINE (moderate certainty).
1 finding from 1 review
Weight: 2a. BMI ‐ Increase · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
It is very uncertain whether SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN changes weight: 2a. BMI ‐ Increase compared with CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐… (very low certainty).
1 finding from 1 review